Monoclonal antibodyFDA-approvedFirst-line
Avastin
Generic name: bevacizumab
How it works
Blocks the formation of new blood vessels that feed cancer cells, starving them of nutrients and oxygen.
Cancer types
Colorectal Cancer— All patients
Lung Cancer— All patients
Efficacy
In clinical trials, Avastin improved progression-free survival and overall response rates in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Bevacizumab May Help Prevent Lung Disease in Lung Cancer Patients | Lung Cancer | observational | Bevacizumab use was associated with lower risks of ILD [SHR, 0.75; 95% confidence interval (CI), 0.67-0.84], 180-day mortality (HR, 0.61; 95% CI, 0.57-0.66), and mortality within 30 days after ILD (HR, 0.71; 95% CI, 0.57-0.88). | Source → |
| Combining Chemotherapy and Surgery for Colorectal Cancer | Colorectal Cancer | phase-2 | Neoadjuvant therapy with mFOLFOXIRI plus bevacizumab can reduce peritoneal tumor burden without increasing surgical risk, and may improve progression-free survival. | Source → |
| Testing a New Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a New Treatment for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Evaluating Treatments for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Ovarian Cancer Treatment Trial Investigates New Combination Therapy | Ovarian Cancer | phase-2 | — | Source → |
| Combining furmonertinib and bevacizumab improves survival in lung cancer patients | Lung Cancer | phase-2 | Combination therapy with bevacizumab plus high-dose furmonertinib significantly improved the LM response compared to that of furmonertinib monotherapy (median iPFS: 6.77 vs 4.04 months, respectively, 95% CI: 0.41-0.98, p = 0.038; median OS: 15.31 vs 7.10 months, respectively, 95% CI: 0.29-0.82, p = 0.002). | Source → |
| Lung Cancer Brain Metastases Treatment Trial | Lung Cancer | phase-3 | — | Source → |
| Testing Oregovomab with Chemo and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Osimertinib and Bevacizumab for EGFR Positive Non-Small Cell Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | — | Source → |
| Testing Ivonescimab and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Testing Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating Pumitamig and Bevacizumab in Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Evaluating Treatment Options for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Bevacizumab Added to Chemotherapy May Improve Lung Cancer Progression-Free Survival | Lung Cancer | phase-3 | The hazard ratio for progression-free survival was 0.69 (95% CI 0.52-0.92) in favor of the bevacizumab group. | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Bevacizumab in Rare Solid Tumors | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Cannabidiol and Bevacizumab Combo Tested | Lung Cancer | lab-study | The apoptotic rate was 15.23% ± 0.42 following cannabidiol treatment and 21.97% ± 0.50 following bevacizumab treatment, and combined treatment significantly increased apoptosis to 50.47% ± 0.67 (< 0.001). | Source → |
| Combination Therapy Extends Survival in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The median overall survival was 8.9 months for FTD-TPI+bev and 5.8 months for FTD-TPI (P<0.001). | Source → |
| US Doctors' Choices for Treating Advanced Colorectal Cancer | Colorectal Cancer | observational | — | Source → |
| Bevacizumab Not Cost-Effective for Some Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| Researchers Identify New Pathway Behind Bevacizumab Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Long-Term Survival in Advanced Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Niraparib May Offer Better Progression-Free Survival for Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 13.77 months in the bevacizumab group. | Source → |
| Bevacizumab's Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| ERBB2-amplified colorectal cancer patients have poorer outcomes with current treatments | Colorectal Cancer | observational | Median progression-free survival was 7.6 months for ERBB2 amp+ patients compared to 8.7 months for ERBB2 amp- patients. | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Bevacizumab May Reduce Lung Inflammation in Cancer Patients | Lung Cancer | observational | — | Source → |
| Ovarian Cancer Patients on PARP Inhibitors May Face Blood Clot Risk | Ovarian Cancer | observational | Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). | Source → |
| Comparing Bevacizumab Doses in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| USP7's role in ovarian cancer resistance to bevacizumab | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Bevacizumab's Effect on Ovarian Cancer Treatment | Ovarian Cancer | observational | Among patients with high-risk prognostic factors, median real-world time to next treatment was significantly longer with 1L chemotherapy plus bevacizumab (13.6 [12.7-15.9] months) than chemotherapy alone (11.7 [10.6-12.6] months; p = .032). | Source → |
| Bevacizumab's Role in Treating Advanced Ovarian Cancer | Ovarian Cancer | review | — | Source → |
| Bevacizumab May Help Ovarian Cancer Patients Who Can't Have Surgery | Ovarian Cancer | observational | Median overall survival for unresectable patients showed no significant difference, but bevacizumab significantly improved OS in the CPB group (not reached vs.18 months, p = 0.015) | Source → |
| Combination Therapy Shows Promise for Untreated Melanoma Brain Metastases | Melanoma | phase-2 | The brain metastasis response rate was 54.1% (95% CI, 36.9 to 70.5). | Source → |
| Bevacizumab and Chemotherapy Combination Shows Promise in Ovarian Cancer Treatment | Ovarian Cancer | phase-2 | The research group showed a disease remission rate of 80.00% and a treatment effectiveness rate of 95.56%. | Source → |
| Biosimilar CT-P16 Shows Equivalent Efficacy in Lung Cancer Treatment | Lung Cancer | phase-3 | Objective response rates were 45.6% and 46.1% for CT-P16 and EU-bevacizumab, respectively. | Source → |
| Real-world outcomes of ovarian cancer patients on niraparib-bevacizumab maintenance therapy | Ovarian Cancer | phase-2 | Median time to treatment discontinuation was 11.8 months (95% CI 8.7 to 13.5), and median time to next treatment was 14.1 months (95% CI 11.3 to 16.6). | Source → |
| Chemotherapy Combination Shows Promise for Advanced Rectal Cancer | Colorectal Cancer | phase-2 | The response rate to preoperative chemotherapy was 92.3% | Source → |
| Rare Side Effect of Cancer Treatment: A Case Report | Colorectal Cancer | observational | — | Source → |
| Bevacizumab May Cause Delayed Anastomotic Leaks in Colorectal Cancer Patients | Colorectal Cancer | observational | — | Source → |
| Bevacizumab May Help in Advanced Ovarian Cancer | Ovarian Cancer | observational | — | Source → |
| Unclassified TP53 mutations linked to better survival in ovarian cancer patients | Ovarian Cancer | preclinical | Patients with TP53 missense mutations of unknown function had a hazard ratio of 0.43 for overall survival. | Source → |
| Ovarian Cancer Study in Finland Examines Treatment Outcomes | Ovarian Cancer | observational | Bevacizumab treatment at any line at stages III/IV improved OS in the short-term only. | Source → |
| Combining Bevacizumab with Chemotherapy May Help Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 11 months in the group that received bevacizumab and chemotherapy, and 9 months in the group that received chemotherapy alone. | Source → |
| Chemotherapy for Gynecologic Cancers Can Be Very Expensive | Ovarian Cancer | observational | — | Source → |
| Bevacizumab Treatment Extends Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 20 months, and overall survival was 58 months. | Source → |
| Bevacizumab's Place in Lung Cancer Treatment | Lung Cancer | review | — | Source → |
| New Treatment Combination Shows Promise for Ovarian Clear Cell Cancer | Ovarian Cancer | phase-2 | — | Source → |
| New Lab Study Examines Uveal Melanoma Treatments | Melanoma | lab-study | The IC concentration of bevacizumab was 6.945 mg/mL. | Source → |
| Combining IOX1 and Bevacizumab May Help Treat Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Trifluridine/Tipiracil Combinations Show Promise in Advanced Colorectal Cancer | Colorectal Cancer | review | Median overall survival ranged 8.6-14.4 months and median progression-free survival 3.7-6.8 months with FTD/TPI plus bevacizumab in refractory mCRC. | Source → |
| New Treatment Combination Shows Modest Activity in Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%). | Source → |
| New Insights into Ovarian Clear Cell Carcinoma Treatment | Leukemia | observational | Patients with advanced/relapsed OCCC who received platinum-based chemotherapy plus bevacizumab followed by maintenance bevacizumab had a median first-line progression-free survival of 12.2 months. | Source → |
| Osteonecrosis of the jaw linked to bevacizumab after radiation | Colorectal Cancer | observational | — | Source → |
| Cost-effectiveness of bevacizumab biosimilar for ovarian cancer | Ovarian Cancer | phase-3 | — | Source → |
| Combining gene silencing and bevacizumab may help treat colorectal cancer | Colorectal Cancer | animal-study | — | Source → |
| New Treatment Option for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | Median progression-free survival was 8.4 months, and median overall survival was 17.6 months in the SALIRI group. | Source → |
| Combining Drugs May Help Some Lung Cancer Patients | Lung Cancer | preclinical | — | Source → |
| Ovarian Cancer Patients Treated with Bevacizumab May Not Experience Deterioration in Quality of Life | Ovarian Cancer | meta-analysis | — | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.